Christian Fischer

USPTO Granted Patents = 19 (Patent Applications = 7)

CIPO Patents = 1

EPO Patents = 13 (Patent Applications = 10)

Average Co-Inventor Count = 11.7

ph-index = 6

Forward Citations = 79(Granted Patents)

Location History:

Boston, MA (US) (2019)
Natick, MA (US) (2012 - 2022)

Company Filing History:

18 out of 2,405

Merck Sharp + Dohme Corp.

1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2012-2025

where 'Filed Patents' based on already Granted Patents

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12215116 - Arginase inhibitors and methods of use (2025-02-04),

2. 11274111 - Arginase inhibitors and methods of use (2022-03-15),

3. 10975084 - KDM5 inhibitors (2021-04-13),

4. 10508108 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-12-17),

5. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),

6. 10086000 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2018-10-02),

7. 9416111 - Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors (2016-08-16),

8. 9376418 - Substituted pyridine spleen tyrosine kinase (SYK) inhibitors (2016-06-28),

9. 9290490 - Aminopyrimidines as Syk inhibitors (2016-03-22),

10. 9242984 - Pyrazolyl derivatives as Syk inhibitors (2016-01-26),

11. 9216173 - 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors (2015-12-22),

12. 9145391 - Bipyridylaminopyridines as Syk inhibitors (2015-09-29),

13. 9023865 - Compounds that are ERK inhibitors (2015-05-05),

14. 8999957 - Heterocyclic compounds as ERK inhibitors (2015-04-07),

15. 8871796 - Diaryl ether derivatives as notch sparing gamma secretase inhibitors (2014-10-28),

Title: Christian Fischer: Innovator in Arginase Inhibition

Introduction

Christian Fischer, based in Natick, MA, holds an impressive portfolio of 19 patents. His work primarily focuses on developing compounds that serve as arginase inhibitors, which hold significant potential for treating arginase-related diseases. Through his innovative research, Fischer has positioned himself as a key figure in the field of pharmaceutical chemistry.

Latest Patents

Fischer's latest patents include detailed descriptions of compounds of Formula I and their pharmaceutically acceptable salts. These compounds act as arginase inhibitors, offering promising avenues for the prevention, treatment, or remediation of diseases linked to arginase activity. His dedication to advancing medical science is evident in the thorough explanations provided in these patents.

Career Highlights

Throughout his career, Christian Fischer has made substantial contributions while working with notable companies in the pharmaceutical industry. He has spent a significant portion of his professional journey at Merck Sharp & Dohme Corporation and Merck Canada Inc. His experience in these prestigious organizations has allowed him to refine his expertise and drive meaningful innovations within the sector.

Collaborations

Fischer's collaborative efforts have also been noteworthy, particularly his work alongside talented colleagues such as Michael D Altman and John Michael Ellis. These partnerships have likely fostered a rich exchange of ideas and knowledge, further enhancing the innovative nature of Fischer’s contributions to medicinal chemistry.

Conclusion

Christian Fischer exemplifies the spirit of innovation in the field of pharmaceuticals, with his extensive patent portfolio reflecting his commitment to addressing complex medical challenges. His work on arginase inhibitors not only showcases his talent as an inventor but also underscores the importance of collaboration in driving forward groundbreaking solutions in healthcare.

This text is generated by artificial intelligence and may not be accurate.